PD-1 Inhibitor Boosts Survival in Treated Esophageal Cancer Benefit with China-developed tislelizumab in all patients and EU-North American subgroup Jul 06, 2021
Infusion Centers or EDs for Sickle Cell Crises? Adults with SCD treated in infusion centers had improved outcomes in three key measures Jul 06, 2021
COVID Surges Emerge; FDA Warns About Chantix; Lions, Tigers, Bears Get Vaxxed A daily roundup of news on COVID-19 and the rest of medicine Jul 06, 2021
Woman Loses 6-Year Battle With Mouth Tumor Rare ameloblastoma rapidly recurs and metastasizes despite numerous radical excisions Jul 04, 2021
Are Antibiotics Linked to Early-Onset Colorectal Cancer? With cases increasing globally, researchers look to these commonly used drugs Jul 03, 2021
IVF Babies at No Increased Risk of Childhood Cancers No associations seen with intracytoplasmic sperm injection or frozen embryo transfer, study found Jul 02, 2021
House Members Argue for Puerto Rico Coal Plant Shutdown Plant is releasing toxic coal ash, sickening the nearby community, lawmakers and witnesses say Jul 01, 2021
'Clinically Meaningful' Survival Gain in Neuroendocrine Tumors Near 1-year improvement with radionuclide agent misses statistical significance Jul 01, 2021
Adjuvant Combo Boosts Survival in Resected Pancreatic Cancer Four-month gain in OS with the addition of nab-paclitaxel to gemcitabine Jun 30, 2021
LDCT Screening Linked to Lower Risk of Brain Mets in Lung Cancer This observed reduction in risk may be due to a less aggressive tumor biology, said study author Jun 28, 2021
Do 'Robots' Offer Any Clear Surgical Advantage? Review says no, and Vinay Prasad believes it's a sobering reflection on medical technology Jun 28, 2021 video
Adding PD-1 Inhibitor Shows Promise in Potentially Resectable HCC "Safe and successful conversion therapy" with hepatic arterial infusion chemo plus sintilimab Jun 28, 2021
Ethics Consult: Help Family Have 'Savior Child' for Marrow Donation? MD/JD Weighs In You voted, now see the results and an expert's discussion Jun 25, 2021
Hold Off on Approving Anal Cancer Drug, Advisors Tell FDA ODAC recommends deferring approval of new PD-1 inhibitor until confirmatory trial results are in Jun 24, 2021
No Survival Benefit With All-Oral Regimen for Relapsed/Refractory Myeloma Prolonging PFS a positive, as advances make OS improvement harder to achieve Jun 18, 2021
AI for Radiation Therapy Works, but Is it Fully Trusted? Most machine learning-generated plans selected over human plans in head-to-head comparison Jun 16, 2021
Start Thinking 'Cure'; One More Hug; Mortgages and Breast Cancer Survival News, features, and commentary about cancer-related issues Jun 16, 2021
What's Guiding Prostate Cancer Care for Gay Men? Research specific to this group has only scratched the surface Jun 16, 2021
Fixed-Duration, All-Oral Regimen Slows CLL Progression Near-80% reduction in PFS hazard with ibrutinib-venetoclax versus obinutuzumab-chlorambucil Jun 16, 2021
The FDA Is Failing the American People The agency's recent decision to approve aducanumab offers more evidence of a broken system Jun 16, 2021
How CAR T-Cell Therapy Measures Up in Follicular Lymphoma Better response rates and survival with axicabtagene ciloleucel versus external control group Jun 15, 2021
Zanubrutinib Tops Ibrutinib in Relapsed or Refractory CLL Better overall response rate, less cardiotoxicity, with second-generation BTK inhibitor Jun 14, 2021
Tweaking Maintenance Options in Metastatic CRC Two studies move the needle, but no major breakthroughs Jun 11, 2021
Most Older Women Do Not Meet Criteria to Stop Cervical Cancer Screening Inadequate screening in middle age, lack of medical record documentation highlighted Jun 10, 2021
COVID Vaccine Protection; 'Until You Die From the Cancer'; What's Palliative Care? News, features, and commentary about cancer-related issues Jun 10, 2021
Bispecific Antibody Active in NRG1-Positive Pancreatic Cancer Zenocutuzumab turns in promising results in early-phase trial involving multiple solid tumors Jun 10, 2021
Promising Early Data for Bladder-Sparing Cancer Treatment Bladder-intact DFS at 1 year nears 90% for muscle-invasive bladder cancer Jun 09, 2021
TRK Inhibitor Proves Beneficial in Primary CNS Tumors One-year OS rate with larotrectinib was 85% Jun 09, 2021
New Standard for Metastatic Castration-Sensitive Prostate Cancer? Triplet regimen reduced the risk for radiographic progression or death, but OS data await Jun 09, 2021
More Support for Gene Assay to Guide Breast Cancer Treatment More nuanced data on treatment de-escalation, extended endocrine therapy Jun 09, 2021
Another CAR-T Impresses in Follicular Lymphoma Complete responses in 66% of patients with relapsed or refractory disease Jun 08, 2021
BPAs Cut Fracture Risk in Metastatic Prostate Cancer Those receiving enzalutamide with and without radium-223 saw benefits in updated safety analysis Jun 08, 2021
Acalabrutinib Offers Less Wear and Tear on the Heart in CLL Patients BTK inhibitor had less cardiotoxicity than ibrutinib, but similar efficacy Jun 07, 2021
Adjuvant Anti-PD-1 Misses on OS in High-Risk Melanoma But pembrolizumab topped active controls for relapse-free survival Jun 07, 2021
Combination Shows Promise in Post-Osimertinib Lung Cancer Responses in 36% with amivantamab-lazertinib, 47% with EGFR/MET resistance Jun 06, 2021
Novel CDK 4/6 Inhibitor Proves Mettle in HR+/HER2- Advanced Breast Cancer Dalpiciclib may be a new treatment option; palbociclib and ribociclib continue to shine Jun 06, 2021
Perioperative Chemo Enough in Esophageal Cancer? MAGIC/FLOT regimens yielded similar overall survival to multimodal CROSS regimen Jun 06, 2021
CAR-T Drives High Response in Relapsed/Refractory ALL ZUMA-3 study shows brexucabtagene autoleucel offers long-term clinical benefit Jun 06, 2021
Antibody-Drug Conjugate Active in Resistant Lung Cancer Responses in 39% of EGFR inhibitor-resistant patients with patritumab deruxtecan Jun 05, 2021
Chemoimmunotherapy Tied to Better Outcomes in Advanced NSCLC PD-L1 status and age play key roles in success of combined regimen versus immunotherapy alone Jun 05, 2021
